PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.43%
Revenue growth similar to TSM's 11.31%. Walter Schloss would see if both companies share industry tailwinds.
14.79%
Gross profit growth 1.25-1.5x TSM's 11.96%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
19.89%
EBIT growth above 1.5x TSM's 12.47%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
19.89%
Operating income growth above 1.5x TSM's 12.47%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
33.41%
Net income growth above 1.5x TSM's 12.25%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
31.43%
EPS growth above 1.5x TSM's 12.09%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
36.36%
Diluted EPS growth above 1.5x TSM's 12.09%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.50%
Share count expansion well above TSM's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
No Data
No Data available this quarter, please select a different quarter.
7.80%
Maintaining or increasing dividends while TSM cut them. John Neff might see a strong edge in shareholder returns.
17.37%
OCF growth under 50% of TSM's 101.28%. Michael Burry might suspect questionable revenue recognition or rising costs.
-13.42%
Negative FCF growth while TSM is at 233.27%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
121.65%
10Y revenue/share CAGR under 50% of TSM's 336.78%. Michael Burry would suspect a lasting competitive disadvantage.
169.14%
5Y revenue/share CAGR above 1.5x TSM's 98.69%. David Dodd would look for consistent product or market expansions fueling outperformance.
109.03%
3Y revenue/share CAGR above 1.5x TSM's 42.37%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
392.59%
10Y OCF/share CAGR above 1.5x TSM's 193.93%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
208.14%
5Y OCF/share CAGR above 1.5x TSM's 84.25%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
175.44%
3Y OCF/share CAGR above 1.5x TSM's 30.90%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
298.40%
Below 50% of TSM's 670.21%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
557.65%
5Y net income/share CAGR above 1.5x TSM's 146.00%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
419.83%
3Y net income/share CAGR above 1.5x TSM's 44.67%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
161.35%
10Y equity/share CAGR at 50-75% of TSM's 246.70%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
58.37%
5Y equity/share CAGR at 50-75% of TSM's 99.12%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
51.85%
3Y equity/share CAGR 1.25-1.5x TSM's 39.06%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
98.71%
Below 50% of TSM's 528.53%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
76.81%
3Y dividend/share CAGR at 50-75% of TSM's 131.58%. Martin Whitman might see a weaker short-term approach to distributing cash.
8.40%
Our AR growth while TSM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-7.12%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
14.35%
Asset growth above 1.5x TSM's 6.10%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
17.03%
BV/share growth above 1.5x TSM's 5.41%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.50%
We’re deleveraging while TSM stands at 37.96%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
9.96%
R&D growth drastically higher vs. TSM's 8.24%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
3.77%
SG&A declining or stable vs. TSM's 14.75%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.